RhoVac publishes research results prior ASCO's meeting
Another clean interim safety review of RhoVac's clinical phase IIb study in prostate cancer
RhoVac — Good execution in challenging times for industry - Edison Group
spotlight_group_logo_cmyk.png
Market Notice 23/22 – Information regarding the rights issue from Rhovac AB
Nyemission i RhoVac AB på Spotlight - Aktier
RhoVac Participates in BIO Europe Digital
Market Notice 56/22 - Last day of trading in RhoVac AB's BTU
RhoVac appoints Professor Georg Holländer to its Scientific Advisory Board
Share Information | Chosa Oncology
Market notice 94/22 – RhoVac AB´s financial instruments are moved to the Observation List
RhoVac aktie (RHOVAC) | Alla nyheter, analys, riktkurs… - Börskollen
RhoVac's reports positive results from the 12 months follow-up of the company's phase I/II clinical study
RhoVac — Good execution in challenging times for industry - Edison Group
RhoVac AB (under name change to Chosa Oncology AB) - Stock and Shares News | IPO HUB
Sweden's RhoVac Aims To Become An M&A Target :: Scrip
The Canadian Intellectual Property Office intends to grant RhoVac's patent application for RV001 (onilcamotide) cancer vaccine
RhoVac AB receives approval to start clinical phase IIb study in Denmark
RhoVac — Stopping metastasis in its tracks - Edison Group
RhoVac's CEO, Anders Månsson, has tendered his resignation
139/19 – Information regarding the rights issue from RhoVac AB
RhoVac AB (under name change to Chosa Oncology AB) - Stock and Shares News | IPO HUB
RhoVac receives approval in Sweden to start clinical phase IIb trial
RhoVac — Good execution in challenging times for industry - Edison Group
RhoVac — Good execution in challenging times for industry - Edison Group
